SOUTH
SAN FRANCISCO, California and VANCOUVER,
Canada, June 6, 2023
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:
EPIX), a clinical-stage pharmaceutical company focused on
developing novel therapies for the treatment of prostate cancer,
today announced the appointment of Lauren
Merendino, M.B.A., to its Board of Directors. Ms. Merendino
is a leading biopharmaceutical executive who brings over 25 years
of commercial experience spanning 20+ disease states, including 15
years of leadership for oncology-specific portfolios.
"Lauren's cross-functional expertise in guiding products through
all stages of commercial development adds a valuable perspective
that complements the skillset of our Board of Directors," stated
Richard M. Glickman, L.L.D. (Hon),
Chairman of ESSA's Board of Directors. "We warmly welcome her to
the team and are confident that Lauren's proven market acumen will
support ESSA's pipeline advancement and collaborations."
"ESSA's unique program of first-in-class anitens targeting the
N-terminal domain of the androgen receptor brings important
innovation to the prostate cancer clinical landscape," said Ms.
Merendino. "I am delighted to be appointed to ESSA's Board of
Directors and look forward to leveraging my commercial knowledge
and experience in oncological programs to ensure that ESSA's
therapies can be delivered to the patient populations who can
benefit the most."
Ms. Merendino recently joined Day One Biopharmaceuticals as
Chief Commercial Officer, prior to which she was Chief Commercial
Officer at Myovant Sciences. In that role, she led the Commercial
organization including sales, marketing, market access and
analytics, to drive the successful launches of two products across
three indications within two years' time. Previously, Ms. Merendino
served as the Vice President of Neurological Rare Diseases at
Genentech, Inc., where she led a cross-functional team to launch
products in the neurological rare disease therapeutic area and
collaboration efforts across marketing, medical affairs and
government affairs. Ms. Merendino also held positions of increasing
authority at Genentech in commercial organization across sales,
marketing and strategy, with a focus in oncology. Throughout her
career, she has built broad experience in national sales,
marketing, as well as commercial strategies for molecules in early
development and business development deals. She earned her B.S.
degree in Microbiology from Pennsylvania State
University and her M.B.A. in Marketing and Management from
New York University.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of
patients with prostate cancer. For more information, please visit
www.essapharma.com and follow us on Twitter under @ESSAPharma.
Forward-Looking Statement
Disclaimer
This release contains certain information which, as presented,
constitutes "forward-looking information" within the meaning of the
Private Securities Litigation Reform Act of 1995 and/or applicable
Canadian securities laws. Forward-looking information involves
statements that relate to future events and often addresses
expected future business and financial performance, containing
words such as "anticipate", "believe", "plan", "estimate",
"expect", and "intend", statements that an action or event "may",
"might", "could", "should", or "will" be taken or occur, or other
similar expressions and includes, but is not limited to, statements
regarding the Company's plans to leverage Ms. Merendino's
expertise, plans to further ESSA's pipeline and the Company's
development program.
Forward-looking statements and information are subject to
various known and unknown risks and uncertainties, many of which
are beyond the ability of ESSA to control or predict, and which may
cause ESSA's actual results, performance or achievements to be
materially different from those expressed or implied thereby. Such
statements reflect ESSA's current views with respect to future
events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by ESSA as of the date of such statements,
are inherently subject to significant medical, scientific,
business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may
make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining
positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and
economic conditions.
Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein
and in ESSA's Quarterly Report on Form 10-Q dated May 9, 2023 under the heading "Risk Factors", a
copy of which is available on ESSA's profile on EDGAR at
www.sec.gov and on the SEDAR website at www.sedar.com, and as
otherwise disclosed from time to time on ESSA's EDGAR and SEDAR
profiles. Forward-looking statements are made based on management's
beliefs, estimates and opinions on the date that statements are
made and ESSA undertakes no obligation to update forward-looking
statements if these beliefs, estimates and opinions or other
circumstances should change, except as may be required by
applicable United States and
Canadian securities laws. Readers are cautioned against attributing
undue certainty to forward-looking statements.
View original
content:https://www.prnewswire.com/news-releases/essa-pharma-appoints-lauren-merendino-to-its-board-of-directors-301842949.html
SOURCE ESSA Pharma Inc